Chinese researchers from the Shanghai Institute of Materia Medica have proposed a new drug design principle based on "first principles" and a "pulsatile activation" concept, published in Nature. This approach aims to restore physiological rhythms rather than continuously stimulating targets, offering potential hope for bile acid-related liver diseases.
Korean biotech firms CGBio, Handok, LegoChem Biosciences, Lotte Biologics, and Daewon Pharm announced progress in drug development, clinical trials, and international conferences. Highlights include CGBio's spine treatment strategy, Handok's hyperinsulinism drug trial results, LegoChem's partner's cancer drug receiving FDA rare disease designation, Lotte Biologics' participation in Bio USA, and Daewon Pharm's obesity drug pre-clinical results.
METiS TechBio's shares surged 173% on their Hong Kong debut, with the AI-driven drug design start-up raising HK$2.11 billion from its initial public offering
METiS TechBio, an AI-driven drug design start-up, made a strong debut on the Hong Kong stock market, raising HK$2.11 billion. CEO Lai Tsai-Ta compared the company to SpaceX, highlighting its use of AI algorithms for rapid drug development through nano-delivery platforms.
